DaVita (NYSE:DVA) Announces Earnings Results, Beats Estimates By $0.25 EPS

Key Points

• DaVita exceeded quarterly expectations: The kidney-care company reported $3.82 in EPS, beating consensus by $0.25, while revenue reached $3.58 billion versus estimates of $3.52 billion.
• Shares rose 4.9% to $192.93 following the results, with trading volume more than double the stock’s average daily volume.
• Analyst sentiment remains positive overall, with four Buy ratings and three Holds producing a “Moderate Buy” consensus and an average price target of $233.43.

DaVita (NYSE:DVA - Get Free Report) announced its earnings results on Thursday. The company reported $3.82 EPS for the quarter, beating analysts' consensus estimates of $3.57 by $0.25, FiscalAI reports. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The business had revenue of $3.58 billion during the quarter, compared to analysts' expectations of $3.52 billion.

DaVita Stock Up 4.9%

Shares of DVA traded up $9.00 during mid-day trading on Thursday, hitting $192.93. 2,044,062 shares of the company's stock were exchanged, compared to its average volume of 892,619. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49. The stock has a market cap of $12.31 billion, a price-to-earnings ratio of 15.79, a P/E/G ratio of 0.48 and a beta of 0.80. The firm has a fifty day moving average of $180.81 and a two-hundred day moving average of $175.70.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Truist Financial decreased their target price on DaVita from $250.00 to $215.00 and set a "hold" rating for the company in a report on Friday, August 7th. Oppenheimer set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft restated a "buy" rating and set a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Weiss Ratings upgraded DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday, October 9th. Finally, Raymond James Financial set a $220.00 price target on DaVita in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, DaVita currently has an average rating of "Moderate Buy" and an average price target of $233.43.

DaVita Company Profile

DaVita Inc NYSE: DVA is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.